Core Insights - Amarin Corporation reported a total revenue of $62.3 million for Q4 2024, a decrease of 17% compared to $74.7 million in Q4 2023, primarily due to lower net selling prices and reduced volume from U.S. generic competition [5][8][10] - The company ended 2024 with nearly $300 million in cash and no debt, reflecting a disciplined approach to capital management [2][5] - A 1-for-20 ADS ratio change was announced to maintain the company's Nasdaq listing, effective around April 11, 2025 [3][5] Financial Performance - Q4 2024 operating expenses were $43.0 million, down 18% from $49.7 million in Q4 2023 [5][12] - The net loss for Q4 2024 was $48.6 million, compared to a net loss of $5.8 million in Q4 2023, resulting in a basic and diluted loss per share of $0.12 [13][14] - Adjusted net loss for Q4 2024, excluding non-cash expenses, was $8.7 million, compared to an adjusted net loss of $0.9 million in Q4 2023 [14][35] Market Expansion and Product Performance - The company successfully launched VASCEPA/VAZKEPA in six additional global markets, including Italy, China, and Australia, and is progressing in 16 more countries [2][6] - In Italy, national reimbursement for VAZKEPA was secured, with access unlocked in over 50% of the eligible population [6] - U.S. net product revenue for Q4 2024 was $44.2 million, down from $64.9 million in Q4 2023, while European revenue increased to $4.0 million from $1.5 million [10][11] Research and Development - In 2024, Amarin's R&D team published 45 additional studies supporting the benefits of VASCEPA/VAZKEPA, enhancing the understanding of its cardiovascular risk reduction capabilities [7] - The company plans to present further data at the ACC.25 conference in March 2025, focusing on the antioxidant effects of EPA and its role in reducing cardiovascular events [9]

Core Insights - The recent post-hoc analysis of the REDUCE-IT study indicates that icosapent ethyl (IPE) significantly reduces composite cardiovascular (CV) endpoint events by 34% among patients with very well-controlled low-density lipoprotein cholesterol (LDL-C) levels (<55 mg/dL) [1][4] - IPE is positioned as a complementary therapy to existing LDL-C lowering treatments, enhancing cardiovascular outcomes and potentially saving lives [1][2] Company Insights - Amarin Corporation emphasizes the efficacy and safety profile of VASCEPA (icosapent ethyl), advocating its use alongside standard care to mitigate cardiovascular disease risk, which remains the leading cause of death globally [1][2] - The company has a commitment to advancing treatment options for patients with persistent cardiovascular risk despite statin therapy, as evidenced by the incorporation of IPE into multiple global guidelines [2][4] Industry Insights - Elevated LDL-C is recognized as a major cardiovascular risk factor, with recent guidelines recommending LDL-C levels be lowered to <55 mg/dL for high-risk patients [1][2] - The cardiovascular disease landscape shows a pressing need for additional evidence-based therapies beyond standard treatments, particularly for patients with elevated triglycerides who remain at significant risk for cardiovascular events [2][11]

Core Insights - Austrian Health Authorities have approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular event risks in eligible patients, effective April 1, 2025, marking the 10th national reimbursement approval in Europe for this product [1][4]. Group 1: Company Overview - Amarin Corporation is an innovative pharmaceutical company focused on cardiovascular disease management, with a commitment to advancing treatment options for patients worldwide [5]. - The company has offices in multiple locations, including Bridgewater, New Jersey, Dublin, Ireland, and Zug, Switzerland, and collaborates with commercial partners globally [5]. Group 2: Industry Context - Cardiovascular diseases accounted for approximately 35% of all deaths in Austria in 2023, highlighting the urgent need for effective treatment options [2]. - More than 100,000 hospitalizations in Austria in 2023 were due to cardiovascular diseases, with direct and indirect costs estimated at around 4.7 billion euros in 2015 [2]. Group 3: Reimbursement Impact - The reimbursement of VAZKEPA® is seen as a significant advancement in addressing the unmet needs of patients with established cardiovascular disease whose triglycerides remain elevated despite statin treatment [3]. - This decision is expected to alleviate the burden on the healthcare system and improve patient outcomes in secondary prevention of cardiovascular diseases [3].

Group 1 - Amarin Corporation will host a conference call on March 12, 2025, at 8:00 a.m. ET to discuss its fourth quarter and full year 2024 results [1] - The financial results will be released in the pre-market hours on the same day [1] - The call will include a Q&A session with the management team [1] Group 2 - Amarin is an innovative pharmaceutical company focused on cardiovascular disease management, with offices in multiple countries including the United States, Ireland, and Switzerland [3] - The company aims to enhance the scientific understanding of cardiovascular risks that persist beyond traditional therapies [3] Group 3 - Amarin provides various channels for investor communication, including its website and investor relations section, where material information is regularly posted [4] - The company encourages stakeholders to review the information available on these channels [4]

Core Insights - Italy's National Health Service has approved VAZKEPA® (icosapent ethyl) for national reimbursement aimed at reducing cardiovascular risk in eligible high-risk patients, marking Italy as the third EU5 market to grant such reimbursement and the ninth overall in Europe [1][4] - The approval is part of a broader strategy by Amarin Corporation to enhance reimbursement, access, and commercialization in Europe, which has resulted in securing national reimbursement in three EU5 markets and nine European markets overall, covering more than 50% of the established cardiovascular disease population in Western Europe [4][6] - The intellectual property for VAZKEPA in Europe has been extended to 2039, eliminating the risk of early competitive entry prior to patent expiration [5] Industry Context - Cardiovascular disease is the leading cause of death and hospitalization in Italy, with over 217,000 deaths and more than 107,000 hospitalizations annually due to myocardial infarction, indicating a significant need for effective treatment options [2][3] - The approval of VAZKEPA addresses a critical clinical need for patients with established cardiovascular disease and elevated triglycerides, who are at a higher risk of subsequent cardiovascular events despite well-managed LDL-C levels [3] - The endorsement of VAZKEPA by over 50 medical societies globally and its approval in 46 countries for cardiovascular risk reduction highlight the significant potential to benefit millions of patients worldwide [6]

Core Points - Amarin Corporation has appointed Peter Fishman as Chief Financial Officer, effective immediately [1] - Fishman has nearly 20 years of experience in finance, including roles in accounting, financial reporting, treasury, tax, and audit [2] - He has been with Amarin since 2019, serving as the principal financial and accounting officer since October 2024 and as Vice President & Global Controller since October 2022 [2] - Fishman holds a Bachelor of Arts in accounting and an MBA, and is a certified public accountant [3] Company Strategy - The CEO, Aaron Berg, expressed confidence in Fishman's ability to lead the company's financial and business strategy moving forward [2] - Fishman has been integral to Amarin's financing efforts and current cash management strategy [2]

Amarin (AMRN) has been beaten down lately with too much selling pressure. While the stock has lost 19.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measu ...

Core Viewpoint - Amarin Corporation plc reported an adjusted loss of 5 cents per share for Q3 2024, aligning with estimates, but total revenues of $42.3 million fell short of expectations and declined 36% year-over-year due to lower product revenues [1][2]. Financial Performance - The net product revenues from Vascepa, Amarin's sole marketed drug, were $41.9 million, down 36% year-over-year, with U.S. product revenues at $30.6 million, a nearly 51% decline from the previous year [3]. - Licensing and royalty revenues decreased to $0.4 million from $1.2 million in the year-ago period [4]. - Selling, general and administrative expenses were $36.9 million, down almost 18.9% year-over-year, attributed to cost optimization efforts [5]. - Research and development expenses totaled $4.5 million, down almost 11.7% year-over-year [5]. Cash Position - Amarin ended Q3 with cash and investments of $305.7 million, slightly down from $306.7 million in the previous quarter, indicating sufficient funds for ongoing operations [6]. Organizational Restructuring - In July 2023, Amarin implemented a restructuring plan aimed at strengthening its cash runway and reducing cash burn, which included workforce reductions and projected annual savings of $50 million [7]. Stock Performance - Following the earnings announcement, Amarin's shares fell 2.9% in after-hours trading, with a year-to-date decline of 30.8%, contrasting with the industry's decline of 3.2% [2].

Financial Data and Key Metrics Changes - In Q3 2024, Amarin reported total net revenue of $42.3 million, a decrease from $66.1 million in Q3 2023, with net product revenue of $41.9 million and licensing and royalty revenue of $400,000 [38] - U.S. product revenue was $30.6 million in Q3 2024, down from $62.4 million in Q3 2023, attributed to lower net selling prices due to generic competition and decreased volume from CVS's coverage changes [39] - Gross margin declined to 38% in Q3 2024 from 64% in the prior year, primarily due to reduced net selling prices in the U.S. [41] - The company reported a GAAP net loss of $25.1 million for Q3 2024, compared to a $19.3 million loss in the prior year [42] Business Line Data and Key Metrics Changes - European net product revenue increased to $4.3 million in Q3 2024, a $3.5 million increase year-over-year, driven by growth in Spain and the UK [40] - Total operating expenses in Q3 2024 were $41.4 million, a reduction of approximately $10 million compared to the prior year, due to ongoing cost optimization initiatives [42] Market Data and Key Metrics Changes - The U.S. market continues to be the main revenue source, maintaining over 50% market share despite increased generic competition [27] - In Europe, the company has launched in eight countries, representing about half of the market access opportunity, with ongoing efforts to expand access [19] Company Strategy and Development Direction - The company aims to maximize the value of VASCEPA and VAZKEPA by expanding access to at-risk patients globally, particularly in Europe where there is significant untapped potential [21][22] - Amarin is focused on executing strategies to drive access and use of its products, supported by strong scientific validation and a commitment to patient care [22][45] Management's Comments on Operating Environment and Future Outlook - Management highlighted the ongoing global unmet need to reduce cardiovascular disease, which remains the leading cause of death worldwide, emphasizing the importance of expanding access to VASCEPA and VAZKEPA [10][46] - The company remains committed to regaining NASDAQ compliance while focusing on operational performance and maximizing product value [47][48] Other Important Information - Amarin has secured pricing and reimbursement in Greece and Portugal, with ongoing efforts in Italy [26] - The company reported aggregate cash and investments of $306 million as of September 30, 2024, with no debt [43] Q&A Session Summary Question: Expectations for net pricing pressure for VASCEPA - Management expects rebates to continue to increase due to the competitive generic market but believes they can maintain volume and compete profitably [51] Question: Additional trials or data points for reimbursement coverage in the EU and China - Ongoing subgroup analyses in high-risk patient populations may support reimbursement efforts, with a focus on acute coronary syndrome patients [53][55] Question: Momentum in revenue from the rest of the world - Growth is driven by early launches and partnerships in various regions, with positive signs from Australia and China [60] Question: Growth dynamics in Europe - Encouraging growth in the UK and Spain attributed to strategic changes and effective execution [61] Question: Future of net pricing for VASCEPA in the U.S. - Pricing pressure is expected to continue due to the generic environment and a shift towards Medicare Part D [63] Question: Status of share repurchase program and business development opportunities - No shares have been repurchased yet; the focus remains on executing with VAZKEPA and VASCEPA before considering additional assets [68][71]

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------|-------|--------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Third Quarter 2024 Business Update & Financial Results Conference Call | | | | | | | | | | | | | | | | | | October 30, 2024 | | | | | | | | Forward Looking Statements & Discl ...